The Science The Institute The Science Get Involved Healthy aging

Selected Publications

Original Research

1) Walker-Simmons, M., Hollander-Cyzthko, H., Andersen, J.K., and Ryan, C.A. (1984). Wound signals in plants: a systemic plant wound signal alters plasma membrane integrity. Proc. Natl. Acad. Sci. 81: 3737-3741.

2) Hollander-Cythko, H., Andersen, J.K., and Ryan, C.A. (1985). Vacuolar localization of wound-induced carboxypeptidase inhibitor in potato leaves. Plant Physiology 78: 76-79.

3) Andersen, J.K., Zhang, M.B., Zhong, X.H., Rosenberg, Y.Y., and Howard, B.D. (1990). 1-methyl-4-phenyl-1,2,3,6-tetrahdropyridine resistant flat PC12 variants have a partial loss of transformed phenotype. J. Neurochem. 55: 559-567.

4) Urban, P., Andersen, J.K., Hsu, P.P., and Pompon, D. (1991). Comparative membrane localizations and activities of human monoamine oxidases expressed in yeast. FEBS Letters 286: 142-146.

5) Andersen, J.K., Herrup, K., and Breakefield, X.O. (1992). Creation of transgenic mice that over-express MAO-B neuronally. Ann. N.Y. Acad. Sci. 648: 241-243.

6) Titlow, C.C.; Andersen, J.K., Trofatter, J.A., and Breakefield, X.O. (1992). In vitro translation of truncated proteins using RNA generated by SP6 RNA polymerase transcription from PCR products, PCR Methods and Applications 2: 172-174.

7) Andersen, J.K., Garber, D.A., Meaney, C.A., and Breakefield, X.O. (1992). Gene transfer into mammalian CNS using herpes virus vectors: long-term expression of lacZ using a mammalian neural promoter. Hum. Gene Therap. 3: 487-499.

8) Andersen, J.K; Frim, D.M., Isacson, O., and Breakefield, X.O. (1993). Herpes-virus mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cell. Mol.Neurobiol. 13: 503-515.

9) Andersen, J.K., Frim, D.M., Isacson, O., and Breakefield, X.O. (1993). Transgenic mice overexpressing monoamine oxidase B neuronally. Movement Disorders 8: 405.

10) Davar, G., Kramer, M.F., Garber, D., Roca, A.L., Andersen, J.K., Bebrin, W., Coen, D.M., Kosz-Vnenchak, M., Knipe, D.M., and Breakefield, X.O. (1994). Gene transfer to sensory neurons using herpes virus vectors. Gene Therapy 1: S24.

11) Davar, G., Kramer, M.F., Garber, D., Roca, A.L., Andersen, J.K., Bebrin, W., Coen, D.M., Kosz-Vnenchak, M., Knipe, D.M., and Breakefield, X.O. (1994). Comparative efficacy ofexpression of genes delivered to mouse sensory neurons with herpes virus vectors. J. Comp. Neurol. 339: 3-11.

12) Andersen, J.K., Frim, D.M., Isacson, O., and Breakefield, X.O. (1994). Catecholaminergic cell atrophy in a transgenic mouse aberrently overexpressing MAO-B in neurons. Neurodegeneration 3: 97-109.

13) Andersen, J.K., Frim, D.M., Isacson, O., Beal, M.F., and Breakefield, X.O. (1994). Elevation of MAO-B in a transgenic mouse model has no effect on MPTP sensitivity. Brain Res. 656: 108-114.

14) Mo, J.-Q., Hom, D.G., and Andersen, J.K. (1995). Oxidative damage in aged mouse brain correlates with decreases in protective enzymes. Mech. Aging Dev. 81: 73-82.

15) Andersen, J.K., Mo, J.-Q., Koek, L.L., Hom, D.G., and McNeill, T.H. (1996). Effects of buthionine sulfoximide, a synthesis inhibitor of the antioxidant glutathione, on murine nigrostriatal neurons. J. Neurochem. 67: 2164-2171.

16) Wei, Q., Yeung, M., Jurma, O.P., and Andersen, J.K. (1996). Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J. Neurosci. Res. 46: 666-673.

17) Kang, Y., Qiao, X., Jurma, O.P., Knusel, B., and Andersen, J.K. (1997). Cloning of cDNA encoding the mouse glutamyl cysteine synthetase heavy chain subunit and localization of expression in the brain. NeuroReport 8: 2053-2060.

18) Hom D.G., Jiang, D.-M., Hong, E.-J., and Andersen, J.K. (1997). Elevated expression of glutathione peroxidase in PC12 cells results in protection against methamphetamine but notMPTP toxicity. Mol. Brain Res. 46: 154-160.

19) Jurma, O.P., Hom, D.G., and Andersen, J.K. (1997). Decreased glutathione results in calcium-mediated cell death in PC12. Free Rad. Biol. Med. 23: 1055-66.

20) Wei, Q., Jurma, O.P., and Andersen, J.K. (1997). Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells. J. Neurosci. Res. 50: 618-626.

21) Busculio, J., Andersen, J.K., Schipper, H.M., Gilad, G.M., McCarty, R., Marzatico, F., and Toussaint, O. (1998). Stress, Aging, and Neurodegenerative Disorders: Molecular Mechanisms. In: Stress of Life from Molecules to Man. (ed.: P. Csermely) Annals of New York Academy of Sciences, vol. 851, pp. 429-444.

22) Kang, Y., Viswanath, V., Jha, N., Qiao, X.X., Mo, J.-Q., and Andersen, J.K. (1999). Neuronalglutamyl cysteine synthetase mRNA expression in the murine brain: comparison to regional-specific enzyme activity and GSH levels. J. Neurosci. Res. 58: 436-441.

23) Klivenyi, P., Andreassen, O.A., Ferrante, R.J., Dedeoglu, A., Mueller, G. Lancelot, E., Bogdanov, M., Andersen, J.K., Jiang, D., and Beal, M.F. (2000). Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitroproprionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20: 1-7.

24) Viswanath, V., Wu, Z., Wei, Q., Fonck, C., and Andersen, J.K. (2000). Transgenic mice neuronally expressing baculoviral p35 are resistant to diverse types of induced apoptosisincluding seizure-associated neurodegeneration. Proc. Natl. Acad. Sci. 97: 2270-2275.

25) Jiang, D.-M., Akopian, G., Qi., X., Ho, Y.-S., Walsh, J.P., and Andersen, J.K. (2000). Chronicbrain oxidation in a glutathione peroxidase knockout mouse model results in increased resistance to induced epileptic seizures. Exp. Neurol. 164: 257-268.

26) Jha, N., Liu, Y., Lalli, G., Jurma, O.P., and Andersen, J.K. (2000). Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: implications for Parkinson’s disease. J. Biol. Chem. 275: 26096-26101.

27) Andersen, J.K. (2000). What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease? Mech. Ageing Dev. 118: 15-22.

28) Jiang, D.-M., Jha, N., Boonplueng, R., and Andersen, J.K. (2001). Caspase 3 inhibition attenuates hydrogen peroxide-induced DNA fragmentation but not cell death in neuronal PC12cells. J. Neurochem. 76: 1745-1755.

29) Yantiri, F., Gasparian, A., and Andersen, J.K. (2001). Glutamyl cysteine synthetase catalytic and regulatory subunits localize to dopaminergic nigral neurons as well as astrocytes. J. Neurosci. Res. 64: 203-206.

30) Andersen, J.K. (2001). Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson’s disease? “Ageing vulnerability: causes and interventions”, Novartis Foundation Symposium 235, John Wiley and Sons, Inc., pp. 11-25.

31) Viswanath, V., Yantiri, F., Boonplueang, R., Yang, Y., Beal, M.F., and Andersen, J.K. (2001). Caspase-9 activation results in downstream caspase-8 mediated bid cleavage in toxin-induced Parkinson's disease. J. Neurosci. 21: 9519-9528.

32) Jha, N., and Andersen, J.K. (2002). Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease? J. Neurochem. 80: 555-561.

33) Bharath, S., Cochran, B.C., Hsu, M., Liu, J., Ames, B.N., and Andersen, J.K. (2002). Pretreatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson’s disease therapy. Neurotoxicol. 23: 479-486.

34) Cudkowicz, M.E., Pastusza, K.A., Sapp, P.C. Mathews, R.K., Pasinelli, P., Francis, J.W., Jiang, D., Andersen, J.K., and Brown, R.H. Jr. (2002). Survival in SOD1 ALS mice does not vary with CNS glutathione peroxidase activity. Neurology 59(5): 729-734.

35) Peng, J., Wu, Z., Wu, Y., Hsu, M., Stevenson, F.F., Boonplueang, R., Roffler-Tarlov, S.K., and Andersen, J.K. (2002). Inhibition of caspases protects cerebellar granule cells of the weaver mouse from apoptosis and improves behavioral phenotype. J. Biol. Chem. 277: 44285-44291.

36) Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., J., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M.F., DiMonte, D., Volitaskis, I., Ellerby, L., Cherney, R.A., Bush, A.I., and Andersen, J.K. (2003). Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37: 1-20.

37) Kumar, J., Nicholls, D.G., and Andersen, J.K. (2003). Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson’s disease. J. Biol. Chem. 278: 46432-46439.

38) Peng, J., Stevenson, F.F., and Andersen, J.K. (2004). The herbicide paraquat induced dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J. Biol. Chem. 279: 32626-32632.

39) Boonplueang, R., Acopian, G., Walsh, J.P., Liu, S., and Andersen, J.K. (2005). Increased susceptibility of glutathione peroxidase transgenic mice to kainic acid-related seizure activity and hippocampal neuronal cell death due to direct activation of the NMDA receptor via GSSG. Exp. Neurol., 192: 203-214.

40) Schilling, B., Srinivas, B., S, Row, R.H., Murray, J., Cusack, M.P., Roderick A. Capaldi, R.A., Freed, C.R., Prasad, K.N., Andersen, J.K., and Gibson, B.W. (2005). Rapid purification and mass spectrometric characterization of mitochondrial NADH dehydrogenase (complex I) from rodent brain and a dopaminergic neuronal cell line. Mol. Cell. Proteomics 4: 84-96.

41) Hsu, M., Srinivas, B., Subramanian, R., and Andersen, J.K. (2005). Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson’s disease. J. Neurochem. 92: 1091-1103.

42) Bharath, S., and Andersen, J.K. (2005). Protein-S-thiolation: role in mitochondrial dysfunction associated with Parkinson’s disease. Antioxid. Redox Signal 7: 900-910.

43) McCormack, A.L., Atienza, J.G., Johnston, L.C., Andersen, J. K., Vu, S., and Di Monte, D.A. (2005). Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J. Neurochem. 93: 1030-1037.

44) Peng, J., Stevenson, F.F., and Andersen, J.K. (2005). Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantia nigra: implications for Parkinson’s disease. J. Biol. Chem: 280: 29194-29208.

45) Chinta SJ, Kumar MJ, Zhang H, Forman HJ and Andersen JK (2006). Up-regulation of γ-glutamyl transpeptidase (GGT) activity following GSH depletion has a compensatory rather than inhibitory effect on mitochondrial Complex I activity: implications for Parkinson’s disease. Free Radical Biology and Medicine. May 1;40(9):1557-63.

46) Kaur D, Rajagopalan S, Chinta S, Kumar J, DiMonte D, Cherney RA, Andersen JK (2006). Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Research 1140: 188-194

47) Chinta SJ, Rajagopalan S, Butterfield DA, Andersen JK (2006). In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neurosci Lett Jul 10: 402 (1-2): 137-41

48) Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, Andersen JK (2006). Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging. 28: 907-913.

49) Chinta SJ and Andersen, JK (2006). Reversible inhibition of mitochondrial complex I activity following chronic glutathione depletion: Implications for Parkinson's disease. Free Radic Biol Med Nov 1: 41 (9): 1442-8.

50) Peng J, Xie L, Stevenson FF, Melov S, Di Monte DA, Andersen, JK (2006). Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J. Neurosci. 26: 11644-11651.

51) Peng J, Peng L, Stevenson FF, Doctrow SR, Andersen JK (2007). Iron and paraquat as synergestic environmental risk factors in sporadic Parkinson’s disease accelerate age-related neurodegeneration. J. Neurosci. 27:6914-6922.

52) Vali S, Mythri RB, Jagatha B, Jyothi Padiadpu J, Ramanujan KS, Andersen JK, Gorin F, Srinivas BMM (2007). Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: A dynamic model. Neurosci. 149: 917-930.

53) Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Anand Rane A, Nicholls DG, Andersen JK (2007). Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons results in nigrostriatal degeneration. J. Neuroscience 27: 13997-14006.

54) Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, DiMonte D, Macarthur H, and Andersen JK (2008). MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS ONE 3(2): e1616. doi: 10.1371/journal.pone.0001616.

55) Peng J, Xie L, Jin K, Greenberg DA, and Andersen JK (2008). Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute MPTP model of Parkinson’s disease. Neurosci. 153(3): 664-670.

56) Chinta S, Rane A, Poksay KS, Bredesen DE, Andersen JK, and Rammohan R (2008). Coupling endoplasmic reticulum stress to the cell death program in dopaminergic cells: effects of paraquat. NeuroMol. Med, PMID: 18773310.

57) Vali S, Chinta S, Peng J, Sultana Z, Singh N, Sharma P, Sharada S, Andersen JK, and Bharath MMS (2008). Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson’s disease: validation by cell culture data FRBM 45: 1290-1301.

58) Peng J., Stevenson FF., Oo M., and Andersen JK (2009). Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. FRBM 46:312-320.

59) Kaur D., Lee D., Ragapolan S., and Andersen JK (2009). Glutathione depletion in immortalized midbrain derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson’s disease FRBM, PMID: 19118623.

60) Chinta SJ, Poksay KS, Kaundinya G, Hart M, Bredesen DE, Andersen JK, and Rao RV (2009). Endoplasmic reticulum stress-induced cell death in dopaminergic cells: Effect of resveratrol (in press, J. Mol. Neurosci.)

  
X
Buck Institute for age research Extending The Healthy
Years Of Life

Yes! I'd like to support the Buck Institute for Age Research and help scientists in their efforts to add healthy years to our lives.

There are three easy ways to make a gift to the Buck Institute today:

  1. EASY! :Write a check made payable to Buck Institute for Age Research and mail your gift to:
    Office of Development
    Buck Institute for Age Research
    8001 Redwood Boulevard
    Novato, CA 94945
  2. EASIER!! :Call 415-209-2261 and give your credit card number and the amount of your gift over the phone.
  3. EASIEST!!! :Enter the amount you chose to give and click on the Google checkout tab on this page.
* Gifts of stock or planned gifts can also be made - please call 209.2262 for more information All contributions are tax-deductible to the extent of the law. As a donor you will receive our newsletter Healthspan, advance notice of upcoming seminars, invitations to donor-only events, and recognition in our Annual Report of Private Giving.

THANK YOU!

$